Shalini Sharp
CIK 1377202 · EVP, Finance · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.27M
Companies
11
Total Filings
141
Lifetime Open-Market Net
-$18.05M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONC | Director | 9 | $348.27 | $3.1K | $0 | 2 | 2026-06-15 |
| OGN | Director | 2 | $13.60 | $27 | $0 | 6 | 2026-06-15 |
| NBIX | Director | 4,088 | $163.41 | $668.0K | -$156.9K | 9 | 2026-05-29 |
| SEPN | Director | — | $38.83 | — | $0 | 1 | 2025-06-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 8,151 | $184.71 | $1.51M | $0 | 1 | 2024-10-02 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 12,060 | $58.70 | $707.9K | $0 | 5 | 2024-01-23 |
| STRO | Director | — | $25.38 | — | $0 | 5 | 2022-06-08 |
| DTIL | Director | — | $7.49 | — | $0 | 2 | 2021-05-12 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 35,000 | $0.01 | $178 | $0 | 1 | 2021-02-26 |
| RARE | EVP, Finance | 97,812 | $25.91 | $2.53M | -$17.81M | 53 | 2020-10-16 |
| AGEN | Director | 9,280 | $6.96 | $64.6K | -$89.0K | 52 | 2018-06-22 |
Recent Filings · Page 2 of 15
141 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-23 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | NBIX | Mixed | +994 | -$156.9K | EDGAR |
| 2024-05-17 | NBIX | Notice (144) | −1,106 | -$157.0K | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −16,222 | $0 | EDGAR |
| 2024-01-03 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +6,808 | $400.0K | EDGAR |
| 2023-06-13 | OGN | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2023-01-24 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +4,444 | $0 | EDGAR |
| 2022-06-14 | OGN | Grant (A) | — | $0 | EDGAR |
| 2022-06-08 | STRO | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.